PMID- 23408112
OWN - NLM
STAT- MEDLINE
DCOM- 20131231
LR  - 20211021
IS  - 1937-5395 (Electronic)
IS  - 1937-5387 (Print)
IS  - 1937-5387 (Linking)
VI  - 6
IP  - 3
DP  - 2013 Jun
TI  - Pharmaco-mechanic antithrombotic strategies to reperfusion of the infarct-related 
      artery in patients with ST-elevation acute myocardial infarctions.
PG  - 378-87
LID - 10.1007/s12265-013-9448-1 [doi]
AB  - Primary percutaneous coronary intervention is the best treatment of patients with 
      ST elevation myocardial infarction (STEMI). When managing a STEMI patient, our 
      approach must be rapid and aggresive in order to interrupt the pathological 
      process of thrombus formation and stabilization. The therapy must be initiated 
      prior to angiography (pretreatment), continued during the procedure 
      (periprocedural), recovery phase (in-hospital), and follow-up. The treatment 
      strategies resulting in thrombus dissolution/extraction have focused on 
      optimization of both pharmacological and interventional therapies. At present, 
      there is no optimal evidence-based approach to all patients with STEMI, and the 
      treatment of these patients needs to be modified with respect to the risk 
      profile, availability of medical resources, and our experience. In this review, 
      we summarize current pharmacological and interventional strategies used in the 
      setting of STEMI and discuss potential benefits of novel dosing regimens and 
      combinations of drugs and techniques.
FAU - Kala, Petr
AU  - Kala P
AD  - Masaryk University and University Hospital Brno, Jihlavska 20, 625 00 Brno, Czech 
      Republic. kalapetr7@gmail.com
FAU - Miklik, Roman
AU  - Miklik R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20130214
PL  - United States
TA  - J Cardiovasc Transl Res
JT  - Journal of cardiovascular translational research
JID - 101468585
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
MH  - Coronary Artery Disease/complications/diagnosis/*therapy
MH  - Fibrinolytic Agents/adverse effects/*therapeutic use
MH  - Humans
MH  - *Mechanical Thrombolysis/adverse effects
MH  - Myocardial Infarction/diagnosis/etiology/*therapy
MH  - Patient Selection
MH  - *Percutaneous Coronary Intervention/instrumentation
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Risk Factors
MH  - Stents
MH  - Thrombectomy/adverse effects/*methods
MH  - *Thrombolytic Therapy/adverse effects
MH  - Time-to-Treatment
MH  - Treatment Outcome
PMC - PMC3650237
EDAT- 2013/02/15 06:00
MHDA- 2014/01/01 06:00
PMCR- 2013/02/14
CRDT- 2013/02/15 06:00
PHST- 2012/11/27 00:00 [received]
PHST- 2013/01/25 00:00 [accepted]
PHST- 2013/02/15 06:00 [entrez]
PHST- 2013/02/15 06:00 [pubmed]
PHST- 2014/01/01 06:00 [medline]
PHST- 2013/02/14 00:00 [pmc-release]
AID - 9448 [pii]
AID - 10.1007/s12265-013-9448-1 [doi]
PST - ppublish
SO  - J Cardiovasc Transl Res. 2013 Jun;6(3):378-87. doi: 10.1007/s12265-013-9448-1. 
      Epub 2013 Feb 14.